These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12949542)

  • 21. Value drivers in licensing deals.
    Arnold K; Coia A; Saywell S; Smith T; Minick S; Löffler A
    Nat Biotechnol; 2002 Nov; 20(11):1085-9. PubMed ID: 12410249
    [No Abstract]   [Full Text] [Related]  

  • 22. A change in the market--investing in diagnostics.
    Batchelder K; Miller P
    Nat Biotechnol; 2006 Aug; 24(8):922-6. PubMed ID: 16900131
    [No Abstract]   [Full Text] [Related]  

  • 23. Serono changes tack.
    Sheridan C
    Nat Biotechnol; 2006 Jan; 24(1):5. PubMed ID: 16404376
    [No Abstract]   [Full Text] [Related]  

  • 24. Investing in nanotechnology.
    Paull R; Wolfe J; Hébert P; Sinkula M
    Nat Biotechnol; 2003 Oct; 21(10):1144-7. PubMed ID: 14520393
    [No Abstract]   [Full Text] [Related]  

  • 25. Can J & J keep the magic going?
    Taylor A
    Fortune; 2002 May; 145(11):117-20, 122. PubMed ID: 12048959
    [No Abstract]   [Full Text] [Related]  

  • 26. In vitro diagnostics industry news.
    Med Device Technol; 2005 May; 16(4):22-4. PubMed ID: 15941194
    [No Abstract]   [Full Text] [Related]  

  • 27. Chiron's manufacturing misfortunes boost competitors.
    Sheridan C
    Nat Biotechnol; 2005 Oct; 23(10):1191. PubMed ID: 16211043
    [No Abstract]   [Full Text] [Related]  

  • 28. Evolving symbiosis--venture capital and biotechnology.
    Bradford TC
    Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
    [No Abstract]   [Full Text] [Related]  

  • 29. Reverse mergers attract top-tier biotechs in sluggish IPO market.
    Lawrence S
    Nat Biotechnol; 2006 Jun; 24(6):598-9. PubMed ID: 16763574
    [No Abstract]   [Full Text] [Related]  

  • 30. The clinical diagnostic reagents and test kit markets.
    Surg Bus; 1980 Mar; 43(3):44-7. PubMed ID: 10246016
    [No Abstract]   [Full Text] [Related]  

  • 31. Deal watch: M&A activity in 2009.
    Walker J
    Nat Rev Drug Discov; 2010 Feb; 9(2):95. PubMed ID: 20118956
    [No Abstract]   [Full Text] [Related]  

  • 32. Financing and Distribution of Pharmaceuticals in the United States.
    Dabora MC; Turaga N; Schulman KA
    JAMA; 2017 Jul; 318(1):21-22. PubMed ID: 28505252
    [No Abstract]   [Full Text] [Related]  

  • 33. Illumina tussles in court with ABI.
    Powell K
    Nat Biotechnol; 2003 Aug; 21(8):836-7. PubMed ID: 12894184
    [No Abstract]   [Full Text] [Related]  

  • 34. Open source: will you follow the cathedral or the bazaar model?
    Skiba DJ
    Nurs Educ Perspect; 2005; 26(3):184-5. PubMed ID: 16021942
    [No Abstract]   [Full Text] [Related]  

  • 35. A very firm handshake: biotech's growing negotiating power.
    Thiel KA
    Nat Biotechnol; 2005 Oct; 23(10):1221-6. PubMed ID: 16211058
    [No Abstract]   [Full Text] [Related]  

  • 36. Biomanufacturing, from bust to boom...to bubble?
    Thiel KA
    Nat Biotechnol; 2004 Nov; 22(11):1365-72. PubMed ID: 15529157
    [No Abstract]   [Full Text] [Related]  

  • 37. Pfizer jettisons Esperion.
    Shaffer C
    Nat Biotechnol; 2008 Jul; 26(7):724-5. PubMed ID: 18612282
    [No Abstract]   [Full Text] [Related]  

  • 38. In-licensing as a business model.
    Schafer DP
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE36-9. PubMed ID: 12089585
    [No Abstract]   [Full Text] [Related]  

  • 39. Trendspotting: a shift in intellectual property focus.
    Anderegg MH; Thayer JM; Williams KM
    Nat Biotechnol; 2006 Jun; 24(6):609-11. PubMed ID: 16862639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Roche vows to keep Genentech culture.
    Hayden EC
    Nature; 2009 Mar; 458(7236):270. PubMed ID: 19295574
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.